Tollys, a Lyon, France-based developer of a synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy, closed a Series A round of financing totaling €2.3m ($2.5M).
This brings the total amount raised to €6.4M ($6.8M) since the company was founded in 2015.
Founded in 2015 by senior scientists from the European Cancer Research Center of Lyon (CRCL) and the Centre Léon Bérard, and led by Vincent Charlon, CEO, Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor. The company is advancing TL-532, a new cancer immunotherapy to treat various types of cancer. TL-532 is a structurally defined double-stranded RNA, produced synthetically and highly specific to the TLR3 receptor.
Tollys will use the proceeds to manufacture TL-532 and launch the regulatory safety studies required before entry into clinical trials in bladder cancer by late 2021/early 2022.
Three new executives are joining Tollys president Jacques-François Martin on the board of directors. Independent members Dr. Dino Dina, a former CEO of Dynavax corporation and of Chiron Vaccines and Mr Philippe Goupit, a biotech and pharmaceutical industry veteran, are joined by Ms Céline Baque Saint-Olive, CEO of Noraker and a representative of Tollys private investors.
The company has ten staff.
FinSMEs
27/05/2020